131I-Related Adverse Effects in Groups A and B
| Outcome | Group A (rhTSH) | Group B (hypothyroidism) | P |
|---|---|---|---|
| Elevated FSH 6 mo after 131I | |||
| Men | 4/9 (44.4%) | 16/18 (89%) | 0.03 |
| Women | 1/13 (7.7%) | 6/30 (20%) | 0.4 |
| Mean increase of FSH | |||
| Men | 105% | 236% | <0.001 |
| Women | 65% | 125% | <0.001 |
| Hyperamylasemia 48 h after 131I* | 11/30 (36.6%) | 48/60 (80%) | <0.001 |
| Symptoms of acute sialoadenitis up to 7 d after 131I* | 9/30 (30%) | 35/60 (58.3%) | 0.01 |
| Thrombocytopenia (<100,000/mm3) or neutropenia (<1,500/mm3) (lowest count) up to 60 d after 131I† | 2/28 (7%) | 12/56 (21.4%) | 0.1 |
| Mean decrease of neutrophils (considering lowest count)‡ | 20% | 45% | <0.01 |
| Mean decrease of platelets (considering lowest count)‡ | 25% | 52% | <0.01 |
| Increased 8-epi-PGF2α 96 h after 131I | 14/25 (56%) | 45/45 (100%) | <0.001 |
| Mean increase of 8-epi-PGF2α | 60% | 125% | <0.001 |
↵* All symptomatic patients presented with concomitant hyperamylasemia. No cause other than salivary gland damage was suspected for increase in serum amylase in any patient.
↵† One patient showed platelet count of less than 75,000/mm3 and other-neutrophil count of less than 1,000/mm3. Thrombocytopenia or neutropenia was observed 30, 45, and 60 d after 131I administration in 4, 8, and 2 patients, respectively.
↵‡ Lowest platelet count was observed 30, 45, and 60 d after ablation in 20, 44, and 20 patients, respectively. Lowest neutrophil count was observed 30, 45, and 60 d after ablation in 16, 40, and 28 patients, respectively.